X4 Pharmaceuticals (XFOR) Asset Utilization Ratio (2019 - 2025)
X4 Pharmaceuticals (XFOR) posted Asset Utilization Ratio of 0.15 for Q4 2025, down 38.84% on a QoQ basis from 0.25 in Q3 2025, and up 881.82% year-over-year from 0.02 in Q4 2024.
X4 Pharmaceuticals (XFOR) Asset Utilization Ratio (2019 - 2025) Analysis & Trends
X4 Pharmaceuticals' Asset Utilization Ratio history runs 4 years deep, the most recent figure standing at 0.15 for Q4 2025.
- Quarterly Asset Utilization Ratio rose 881.82% year-over-year to 0.15 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.15 (up 881.82% YoY) and the FY2025 annual result came in at 0.16, up 823.12% from the prior year.
- Asset Utilization Ratio was 0.15 for Q4 2025 at X4 Pharmaceuticals, down from 0.25 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.28 in Q2 2025 and bottomed at 0.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 0.69 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | 0.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.15 |
| Sep 30, 2025 | 0.25 |
| Jun 30, 2025 | 0.28 |
| Mar 31, 2025 | 0.23 |
| Dec 31, 2024 | 0.02 |
| Sep 30, 2024 | 0.01 |
| Jun 30, 2024 | 0.00 |
| Dec 31, 2020 | 0.02 |
| Sep 30, 2020 | 0.02 |
| Jun 30, 2020 | 0.02 |
| Mar 31, 2020 | 0.02 |
| Sep 30, 2019 | 0.03 |